Objective:

To introduce a microbubble-based approach for cell selection and activation in cell therapy manufacturing, replacing traditional magnetic beads.

Key Findings:

• Microbubbles can enhance the isolation of immune cell subsets beyond standard CD3+ selection.
• The approach minimizes perturbation of intracellular signaling pathways, providing a cleaner starting point for genetic modification.
• Microbubbles can be easily removed, simplifying workflows compared to bead-based processes.

Interpretation:

Bracco's microbubble technology aims to address key challenges in cell therapy manufacturing by providing a more efficient, scalable, and cleaner method for cell selection and activation.

Limitations:

• The technology is still in the development phase and requires performance validation through partnerships.
• Commercial availability is projected for 2027, which may limit immediate application.

Conclusion:

Bracco's innovative microbubble platform has the potential to revolutionize cell therapy manufacturing by offering a more efficient and less invasive alternative to traditional methods.